Overview

Drug-Drug Interaction (DDI) Study for TPN171H

Status:
Completed

Trial end date:
2020-09-02

Target enrollment:

Participant gender:

Summary

The primary objective of this study was to assess the effect of rifampicin,a cytochrome P450 3A4 enzyme (CYP3A4) induction, on the pharmacokinetics (PK) of TPN171H in chinese healthy male subjects ,and assess the effect of itraconazole，cytochrome P450 3A4 enzyme (CYP3A4) induction on the PK of TPN171H in chinese healthy male subjects

Phase:

Phase 1

Details

Lead Sponsor:

Vigonvita Life Sciences

Treatments:

Itraconazole
Rifampin